BridgeBio’s Encaleret Shows Promising Results in Phase 3 ADH1 Trial, FDA Grants Priority Review
Event summary
- Encaleret increased bone turnover and improved participant-reported symptoms in the Phase 3 CALIBRATE trial for ADH1.
- 100% of participants on encaleret reported symptom improvements vs. 46% on standard care.
- FDA accepted BridgeBio’s NDA for encaleret in ADH1 and granted Priority Review with a PDUFA target action date of May 8, 2027.
- First participant dosed in RECLAIM-HP, a Phase 3 study for chronic hypoparathyroidism.
The big picture
BridgeBio’s encaleret represents a potential breakthrough in treating rare genetic conditions like ADH1 and chronic hypoparathyroidism, where current therapies are limited and often associated with long-term complications. The FDA’s Priority Review designation underscores the unmet medical need and could accelerate encaleret’s path to market, positioning BridgeBio as a key player in the rare disease space. The company’s decentralized model allows for rapid, targeted development, but its success will hinge on sustained clinical and regulatory wins.
What we're watching
- Regulatory Momentum
- Whether the FDA’s Priority Review designation will expedite encaleret’s approval process and set a precedent for other BridgeBio therapies.
- Clinical Efficacy
- How the Phase 3 RECLAIM-HP trial results will compare to the CALIBRATE trial, particularly in chronic hypoparathyroidism.
- Market Expansion
- The pace at which BridgeBio can leverage encaleret’s success to expand into other rare disease indications.